Principal Securities Inc. Increases Position in Enovis Co. (NYSE:ENOV)

Principal Securities Inc. lifted its holdings in shares of Enovis Co. (NYSE:ENOV) by 21.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,649 shares of the company’s stock after acquiring an additional 982 shares during the quarter. Principal Securities Inc.’s holdings in Enovis were worth $248,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ENOV. UMB Bank n.a. boosted its stake in Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock valued at $34,000 after acquiring an additional 437 shares during the period. Pinnacle Bancorp Inc. boosted its position in shares of Enovis by 54.5% during the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock worth $37,000 after buying an additional 300 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in shares of Enovis during the third quarter worth approximately $55,000. FMR LLC lifted its position in Enovis by 20.5% in the third quarter. FMR LLC now owns 2,840 shares of the company’s stock worth $122,000 after purchasing an additional 484 shares during the period. Finally, XTX Topco Ltd acquired a new stake in Enovis in the third quarter worth approximately $217,000. 98.45% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $65.00 price target on shares of Enovis in a report on Thursday, November 7th.

Enovis Price Performance

NYSE ENOV opened at $42.77 on Monday. The stock has a market capitalization of $2.43 billion, a P/E ratio of -19.53 and a beta of 1.94. Enovis Co. has a 1 year low of $38.27 and a 1 year high of $65.03. The business’s fifty day moving average is $45.08 and its two-hundred day moving average is $44.38. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.